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Abstract
Axonal dysfunction is a common phenotype in neurodegenerative disorders, including in amyotrophic lateral sclerosis (ALS), 
where the key pathological cell-type, the motor neuron (MN), has an axon extending up to a metre long. The maintenance of 
axonal function is a highly energy-demanding process, raising the question of whether MN cellular energetics is perturbed in 
ALS, and whether its recovery promotes axonal rescue. To address this, we undertook cellular and molecular interrogation of 
multiple patient-derived induced pluripotent stem cell lines and patient autopsy samples harbouring the most common ALS 
causing mutation, C9orf72. Using paired mutant and isogenic expansion-corrected controls, we show that C9orf72 MNs 
have shorter axons, impaired fast axonal transport of mitochondrial cargo, and altered mitochondrial bioenergetic function. 
RNAseq revealed reduced gene expression of mitochondrially encoded electron transport chain transcripts, with neuropatho-
logical analysis of C9orf72-ALS post-mortem tissue importantly confirming selective dysregulation of the mitochondrially 
encoded transcripts in ventral horn spinal MNs, but not in corresponding dorsal horn sensory neurons, with findings reflected 
at the protein level. Mitochondrial DNA copy number was unaltered, both in vitro and in human post-mortem tissue. Genetic 
manipulation of mitochondrial biogenesis in C9orf72 MNs corrected the bioenergetic deficit and also rescued the axonal 
length and transport phenotypes. Collectively, our data show that loss of mitochondrial function is a key mediator of axonal 
dysfunction in C9orf72-ALS, and that boosting MN bioenergetics is sufficient to restore axonal homeostasis, opening new 
potential therapeutic strategies for ALS that target mitochondrial function.
Keywords Amyotrophic lateral sclerosis · Axon · Energy metabolism · Frontotemporal dementia · Mitochondria · Motor 
neuron · Neurodegeneration
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Amyotrophic lateral sclerosis (ALS) is an incurable, rap-
idly progressive and fatal neurodegenerative disorder, 
characterised by loss of upper and lower motor neurons 
(MNs) [18]. Humans are the only species affected by 
sporadic ALS [8]. Approximately 10–20% of ALS cases 
are familial, of which the C9orf72 hexanucleotide repeat 
expansion mutation is the commonest cause [29, 81]. The 
finding that familial ALS is clinically and pathologically 
indistinguishable from sporadic ALS supports the study of 
monogenetic causes to better understand common patho-
genic mechanisms [67]. Thus, human induced pluripotent 
stem cell (iPSC)-derived MN experimental platforms 
[84], combined with paired gene-edited isogenic control 
lines, provide a powerful approach, both to identify early-
stage disease-driving mechanisms, and establish causal-
ity between a given mutation and phenotypes [31, 85, 91, 
92]. Such in vitro disease modelling is complemented by 
in vivo approaches, particularly those that harness tech-
nologies interrogating molecular neuropathological signa-
tures in human post-mortem tissue [40, 43, 92].
Although a clinical ALS phenotype that includes hyper-
metabolism and dyslipidaemia [32] is well recognised [103], 
there is limited understanding of the underlying mechanism 
and/or connection to MN metabolic state [13, 104, 109]. 
Neurons, in contrast to astrocytes (for example), are pre-
dominantly reliant upon mitochondrial oxidative phospho-
rylation [114]; this, coupled with the extraordinary length of 
MN axons—20,000 times longer than the diameter of their 
soma [47]—suggests a particular metabolic vulnerability of 
MNs to deficits in key processes involved in the mainte-
nance of the form and function of the axon: dysfunctional 
axonal homeostasis. These processes include cytoskeletal 
dynamics and axonal transport. Both axonal growth, as well 
as transport of cargo driven by dynein and kinesin molecu-
lar motors, are energy demanding processes, with kinesin 
hydrolysing one ATP per 8 nm step [38]. Transport of mito-
chondrial cargo, in contrast to vesicular transport, depends 
on mitochondrial ATP, and not glycolysis [113]. Defective 
transport of cargo to the distal axon has been reported in 
several ALS causing mutations [1, 2, 9, 22, 28, 41, 48, 50, 
64, 71, 78, 96], and not just in genes canonically involved 
in microtubule-based transport of cargo [70, 73, 98]. It is 
therefore perhaps surprising that, despite major advances 
in our understanding of the biology and consequence of the 
C9orf72 repeat expansion mutation on MNs [10], its specific 
impact on axonal homeostasis has been relatively understud-
ied, particularly in human models [1, 64, 96]. It remains, for 
example, unknown whether C9orf72 MNs have a metabolic 
deficit, and whether this contributes to axonal dysfunction 
and selective MN vulnerability.
Against this background, we examined the cell-autono-
mous role of mitochondrial bioenergetics on C9orf72 MN 
axonal function using multiple patient-derived iPSCs com-
bined with isogenic controls, transcriptomic analysis and 
human neuropathological study. We establish that C9orf72 
MNs have dysfunctional axonal homeostasis, with aberra-
tions in axonal morphology (reduced neurite length) and 
function (impaired fast axonal transport of mitochondrial 
cargo). We show that these axonal phenotypes are associated 
with concomitant metabolic dysfunction, owing to defec-
tive mitochondrial respiration. Unbiased RNA-sequencing 
revealed reduced expression of electron transport chain tran-
scripts, encoded by mitochondrial DNA, the copy number 
of which was unaltered. Critically, we show, through neu-
ropathological analysis of patient post-mortem tissue, that 
this transcriptomic dysregulation is selective to anterior horn 
spinal (motor) neurons, and is absent in dorsal horn spinal 
(sensory) neurons, with corresponding alterations reflected 
at the level of protein expression. Through manipulation of 
this molecular mitochondrial loss-of-function signature, 
leading to therapeutic rescue of the observed dysfunctional 
axonal homeostasis, we determine a novel causal relation-
ship between axon dysfunction and contributory metabolic 
dysfunction in C9orf72-ALS.
Materials and methods
Cell culture and motor neuron generation 
from parental and gene‑edited human iPSCs
Dermal fibroblasts from two unrelated healthy individuals 
(Con-1, Con-2) and three C9orf72 ALS/FTD patients (C9-
1, C9-2, C9-3) harbouring the  G4C2 repeat expansion in the 
C9orf72 gene were obtained and reprogrammed under full 
Ethical/Institutional Review Board approval at the Univer-
sity of Edinburgh, and isogenic controls were generated 
via CRISPR/Cas9 technology, as previously described by 
our group [92, 105] (Table 1). iPSCs were maintained in 
 Matrigel® Growth Factor Reduced Basement Membrane 
Matrix (354230,  Corning® Life Sciences)-coated plastic 
dishes in E8™ medium (A1517001, Gibco™ Thermo Fisher 
Scientific) at 37 °C and 5%  CO2. Standard Giemsa band-
ing chromosome analysis was periodically performed over 
the course of this study to exclude a karyotypic abnormal-
ity (The Doctors Laboratory Ltd, London), together with 
monthly testing of iPSC culture supernatants to exclude 
mycoplasma contamination using the  Venor®GeM Classic 
detection kit (11-1050, Minerva Biolabs GmbH).
Spinal MN differentiation was performed using an estab-
lished protocol [62] with minor modifications, yielding a 
highly enriched and electrophysiologically mature neuronal 
culture, devoid of glia, with circa 60% of cells being positive 
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for islet-1 and islet-2 homeobox MN markers one week post 
platedown [92]. iPSCs were dissociated into single cells 
using 1X Accutase® (A6964, Sigma-Aldrich®), and neu-
ralised as a suspension culture using dual-SMAD inhibition 
by SB-431542 (20 μM; 1614,  Tocris® Bio-Techne), LDN-
193189 (0.1 μM; S2618, Selleckchem) and potentiation with 
the Wnt-agonist, CHIR-99021 (3 μM; 4423,  Tocris® Bio-
Techne) in N2/B27 medium (0.5X Neurobasal™ [21103049, 
Gibco™ Thermo Fisher Scientific], 0.5X Advanced DMEM/
F12 [12634028, Gibco™ Thermo Fisher Scientific], 1X 
Antibiotic–Antimycotic [15240062, Gibco™ Thermo Fisher 
Scientific], 1X GlutaMAX™ [35050061, Gibco™ Thermo 
Fisher Scientific], 100 μM beta-mercaptoethanol [31350010, 
Gibco™ Thermo Fisher Scientific], 1X B-27™ supplement 
[17504044, Gibco™ Thermo Fisher Scientific], 1X N-2 sup-
plement [17502001, Gibco™ Thermo Fisher Scientific] and 
10 μM l-ascorbic acid [A4403, Sigma-Aldrich®]). On day 
2, neural spheres were simultaneously patterned to spinal 
cord identity by treating with retinoic acid (RA, 0.1 μM; 
R2625, Sigma-Aldrich®) and smoothened agonist (SAG, 
0.5 μM; 566660, Sigma-Aldrich®), promoting caudalisa-
tion and ventralisation, respectively, along with SB-431542, 
LDN-193189 and CHIR-99021 in N2/B27 medium for an 
additional 5 days. On day 7, spheres were maintained in 
culture with RA and SAG, with the addition of recombi-
nant human brain-derived neurotrophic factor (BDNF, 
10 ng/ml; 248-BDB, R & D  Systems® Bio-Techne) in N2/
B27 medium to generate MN progenitors. From day 9, 
MN progenitors were cultured in day 7 medium with the 
addition of DAPT (10 μM; 2634,  Tocris® Bio-Techne), an 
inhibitor of Notch signalling, for an additional 5–7 days. 
At day 14–16, MN spheres were dissociated using 0.05% 
Trypsin–EDTA (25300054, Gibco™ Thermo Fisher Sci-
entific) and cells were plated as a monolayer onto laminin 
from Engelbreth-Holm-Swarm murine sarcoma basement 
membrane (5 μg/ml; L2020, Sigma-Aldrich®), fibronectin 
human plasma (10 μg/ml; F2006, Sigma-Aldrich®), and 
 Matrigel® (1:20)-coated dishes that had been pre-treated 
with poly-l-ornithine bromide (100 µg/ml; P3655, Sigma-
Aldrich®). Dissociated MNs were cultured in motor neu-
ron neurotrophic factor (MN-NF) medium (1X Neurobasal, 
1X Antibiotic–Antimycotic, 1X GlutaMAX™, 1X MEM 
Non-Essential Amino Acids solution [11140–035, Gibco™ 
Thermo Fisher Scientific], 100 μM beta-mercaptoethanol, 
1X B-27™ supplement, 1X N-2 supplement, RA [1 μM], 
ascorbic acid [2.5 μM], BDNF [10 ng/ml], recombinant 
human glial-derived neurotrophic factor [GDNF, 10 ng/
ml; 212-GD, R & D  Systems® Bio-Techne], recombi-
nant human ciliary neurotrophic factor [CNTF, 10 ng/ml; 
257-NT, R & D  Systems® Bio-Techne], and animal-free 
recombinant human insulin-like growth factor-1 [IGF-1, 
10 ng/ml; AF-100–11,  PeproTech®]). MN-NF medium was 












































































































































































































































































































































uridine/5-fluoro-2′-deoxyuridine (1 μM, U/FDU; U3003 and 
F0503, Sigma-Aldrich®) for at least 1 week post platedown 
to remove residual proliferating cells.
Overexpression of PGC1α
Briefly, FLAG-PGC1α-6xHIS (originated from Addgene 
[67637]) and P2A-eGFP (originated from pDONR-P2A-
eGFP), were shuttled into a lentiviral backbone pLenti6-
cppt-delta CMV-DEST-opre, to generate a FLAG-
PGC1α-6xHIS-P2A-eGFP lentiviral construct. PGC1α 
overexpression lentivirus was generated as previously 
described [63, 76] and transduced as previously described by 
our group [56] in human iPSC-derived MNs at a multiplicity 
of infection (MOI) of 10. This achieved a mean transduction 
efficiency of circa 70% MNs. Vehicle control transduction 
was achieved by lentiviral transduction of emerald GFP in 
the equivalent plasmid backbone using a plasmid from Inv-
itrogen™ (Thermo Fisher Scientific, V35520).
Immunocytochemistry and neurite outgrowth 
quantification
MNs plated on 30-mm glass coverslips etched by the pre-
treatment of nitric acid were washed once with phosphate-
buffered saline (PBS; 10010, Gibco™ Thermo Fisher Sci-
entific) and then incubated for 20 min at room temperature 
with 4% paraformaldehyde (AGR1026, Agar Scientific). 
Thereafter, cells were washed three times with PBS, fol-
lowed by incubation for 10  min at room temperature 
with PBS containing 0.2% Triton X-100 (T8787, Sigma-
Aldrich®) for permeabilisation, followed by a 1 h incuba-
tion at room temperature in 6% normal goat serum block-
ing buffer (S-1000, Vector Laboratories) in PBS. Primary 
antibodies diluted in blocking buffer were then added for 
overnight incubation at 4 °C. Cells were washed three times 
in phosphate-buffered saline plus 0.1%  Tween® 20 (PBST; 
P9416, Sigma-Aldrich®) before the secondary antibod-
ies coupled to fluorophores (Alexa  Fluor® range, Thermo 
Fisher Scientific) were added diluted in PBST for 1 h at 
room temperature, with the samples protected from light. 
After washing with PBST, 4′,6-diamidino-2-phenylindole 
(DAPI, 1 µg/ml diluted in PBS; 10236276001, Roche) was 
applied for nuclear counterstaining for a further 15 min. 
Coverslips were then washed with PBST and distilled water, 
and then mounted onto glass slides (12362098, Thermo 
Fisher Scientific) with FluorSave™ Reagent (345789, Mil-
lipore) and imaged using an Axio Observer Z1 inverted 
motorised microscope (Carl Zeiss). Images were acquired 
from random positions of the coverslip. Primary antibod-
ies used in this study are as follows: SMI-312 at 1:1000 
(837904,  BioLegend®), GFP at 1:1000 (ab13970, Abcam), 
and PGC1α at 1:300 (ab54481, Abcam). Neurite outgrowth 
was quantified 7 days post platedown (plating density of 
5000 MNs per coverslip) blinded to sample genotype using 
the Simple Neurite Tracer plugin [58] within Fiji [89].
RNA extraction, RNA sequencing and transcriptomic 
analysis
Total RNA was extracted from MNs from two independ-
ent isogenic-corrected paired cell lines and two independ-
ent control cell lines (C9-1 and C9-2; Con-1 and Con-2) at 
day 21 post platedown using the  RNeasy® Mini kit (74104, 
 Qiagen®), according to the manufacturer’s instructions. RNA 
samples were assessed for concentration (NanoDrop ND-100 
Spectrometer, NanoDrop Technologies) and quality (Agi-
lent 2200 TapeStation, Agilent Technologies) before library 
preparation. Library preparation and sequencing were car-
ried out by Edinburgh Genomics (Edinburgh, UK). For each 
sample, cDNA was converted to a sequencing library using 
the TruSeq stranded mRNA-seq library. Barcoded librar-
ies were pooled and sequenced on an Illumina HiSeq 4000 
using 75 base paired-end reads to generate at least 46 million 
raw reads per sample. The reads were mapped to the primary 
assembly of the human (hg38) reference genome contained 
in Ensembl release 90 [25]. Alignment was performed with 
STAR version 2.5.3a [30]. Tables of per-gene read counts 
were generated from the mapped reads with featureCounts 
version 1.5.2 [55]. Differential gene expression analysis, 
using DESeq2 version 1.16.1, specifically examined the 
intersection in commonly and concordantly differentially 
expressed genes between the two mutant-isogene pairs, 
using a false discovery rate of 20%, achieved by setting a 
Benjamini–Hochberg corrected p value threshold of 0.2 
(genes with an average Fragments Per Kilobase of transcript 
per Million mapped reads [FPKM] < 1 were disregarded). 
Gene ontology (GO) [5, 100] analysis was performed on the 
differentially expressed genes to identify putatively altered 
pathways or processes using the GeneRanker module [11] 
within Genomatix proprietary software suite (Intrexon Bio-
informatics Germany GmbH; threshold: p ≤ 0.01, Fisher’s 
exact test). Competitive gene set testing was performed 
using CAMERA [110]. Promoter analysis was performed 
using default parameters within Genomatix; first, the Gene-
2Promoter module was used to extract promoter sequences 
of all significantly dysregulated genes annotated in hg38. 
Overrepresented transcription factor binding sites (TFBS) 
were searched using MatBase within the input regions, and 
statistics on TFBSs were generated, together with over-
representation values and Z-scores (the distance from the 
population mean in units of the population standard devia-
tion) compared against genomic and promoter background. 
Promoter associations were defined as transcription factor 
families known to occur more than twice as often in promot-
ers as in genomic sequence. A Z-score below -2 or above 2 
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can be considered statistically significant (it corresponds to 
a p value of ~ 0.05).
Quantitative reverse transcription PCR
Total RNA was extracted using the  RNeasy® Mini kit 
(74104,  Qiagen®), according to the manufacturer’s instruc-
tions. Genomic DNA was removed using the on-column 
DNase method (79254,  Qiagen®). cDNA was synthesised 
using 250 ng of RNA using the DyNAmo™ cDNA Synthe-
sis Kit (10748908, Thermo Fisher Scientific). Technical rep-
licates, as well as no template and no RT negative controls, 
were included, and at least three biological replicates were 
studied in each case. Real-time reverse transcription quanti-
tative PCR (RT-PCR) reactions were set up with DyNAmo 
ColorFlash SYBR Green qPCR kit (10442308, Thermo 
Fisher Scientific) and run on a CFX96 System (Bio-Rad). 
The data were visualised and exported using Maestro 1.1 
software (Bio-Rad). Primers were synthesised by Sigma-
Aldrich®. Primer sequences and annealing temperatures 
used in this study are provided in Supplementary Table 1, 
online resource.
Assessment of in vitro mitochondrial copy number
MNs, plated at a density of 2–4 million cells per 60 mm 
dish (430166,  Corning® Life Sciences), were lysed at day 
14 post platedown using 200 µl of Bradley Lysis buffer 
(10 mM Tris–HCl pH 7.5, 10 mM EDTA pH 8.0, 0.5% w/v 
SDS, 10 mM NaCl) containing 0.2 mg/ml of fresh Protein-
ase K (AM2546, Ambion™) and incubated in locking-lid 
microfuge tubes at 55 °C overnight on a  ThermoMixer® 
comfort (Eppendorf AG) [80]. Subsequent steps are derived 
from classical techniques for genomic DNA extraction 
using phenol-choloroform [83]. An equal volume of phe-
nol/choloroform/isoamyl alcohol solution (25:24:1; P2069, 
Sigma-Aldrich®) was added to each sample. After vortexing, 
organic and aqueous phases were separated by centrifuga-
tion at 16,000 rcf for 5 min. The upper aqueous phase was 
transferred to a new microfuge tube, and 200 µl of elution 
buffer (pH 8; 11–05-01–13, Integrated DNA Technologies, 
Inc) was added the original tube, which was vortexed and 
centrifuged as previously. The upper aqueous phase was 
transferred and combined with that obtained previously. An 
equal volume of chloroform/isoamyl alcohol solution (24:1; 
25666, Sigma-Aldrich®) was added (choloroform back-
extraction step). Following vortexing and centrifugation, the 
upper aqueous phase was transferred into a new microfuge 
tube, to which ammonium acetate (A2706, Sigma-Aldrich®) 
was added to a final concentration of 0.75 M, together with 
20 µg of glycogen (9510, Ambion™). After mixing well, 
2.5X volume of 100% ethanol was added. After a short 
20 °C incubation on a  ThermoMixer®, the samples were 
centrifuged at 4 °C at 16,000 rcf for 20 min. The supernatant 
was carefully decanted, and the pellet washed with 300 µl 
of cool 80% ethanol. After vortexing the samples, they were 
centrifuged at 16,000 rcf for 15 min at 4 °C. The supernatant 
was again carefully decanted and the pellet washed for a 
second time with 80% ethanol, followed by vortexing and 
centrifugation. The ethanolic solution was carefully aspi-
rated and the pellet air dried at room temperature for 5 min 
followed by resuspension of the pellet in elution buffer, with 
gentle rocking overnight at 4 °C. Samples were assessed 
for concentration and quality using a NanoDrop ND-100 
Spectrometer and stored at 4 °C for the duration of the study.
Mitochondrial DNA content was assessed by quantifica-
tion of a unique (and rarely deleted) mitochondrial fragment 
in the minor arc of the mitochondrial genome (MT-ND1) 
relative to a single copy region of a nuclear gene (beta-2 
microglobulin, B2M) using an established method [19, 39, 
44, 61]. First, a customised double-stranded ND1–beta-2 
microglobulin DNA fragment of 255 base pairs was syn-
thesised as a gBlocks™ Gene Fragment (Integrated DNA 
Technologies, Inc.; sequence: 5′-TGC ATG ATC TAC GTG 
CGT CAC ATG CAG TAC CCA GCA GAG AAT GGA 
AAG TCA AAT TTC CTG AAT TGC TAT GTG TCT GGG 
TTT CAT CCA TCC GAC ATT GAA GTT GAC TTA CTG 
AAG AAT GGA GAG AGA CAC TAG CTC AGA TTC 
AGT AGA CCG CTG TTG CCC TAA AAC CCG CCA 
CAT CTA CCA TCA CCC TCT ACA TCA CCG CCC CGA 
CCT TAG CTC TCA CCA TCG CTC TAG TAA TGC AGA 
CAC TTG CGG TCC ATC TCG-3′). Serial dilutions were 
generated at 1:10 increments between 1 × 10–8 ng/µl and 
10 ng/µl and stored at 4 °C for the duration of the study. 
Copy number was calculated as follows:
where C is the concentration of the gBlocks™ Gene Frag-
ment in ng/µl, and M is the molecular weight (specified as 
6.35 fmoles/ng).
A standard curve was generated. Real-time quantitative 
PCR (qPCR) reactions of the standards and the samples were 
set up in triplicate per experiment with DyNAmo Color-
Flash SYBR Green qPCR kit (10442308, Thermo Fisher 
Scientific) and run on a CFX96 System (Bio-Rad). The data 
were visualised and exported using Maestro 1.1 software 
(Bio-Rad). Primers were synthesised by Sigma-Aldrich®. 
Primer sequences for ND1 and beta-2 microglobulin, and 
their annealing temperatures, are provided in Supplementary 
Table 1, online resource. To ensure the sample quantifica-
tion cycles (Cq) for both reactions were within an optimal 
detection range of 17–33 [39], sample DNA concentrations 
differed by an order of magnitude between the mitochondrial 
(0.02X) and nuclear (1X) reactions. A standard curve of 




mean Cq value (ordinate) versus copy number (abscissa) 
was generated for both ND2 and beta-2 microglobulin, and 
copy numbers for each sample were interpolated using the 
semi-log line least squares fit function within Prism version 
9.0.0 (GraphPad Software). The interpolated mitochondrial 
copy number was divided by the interpolated nuclear copy 
number to generate ratios of normalised values. Each experi-
ment was performed at least three times (i.e., from at least 
three MN differentiations per cell line).
Western blot
MNs were cultured for 3  weeks. MN-NF medium was 
removed and cells were washed with ice-cold PBS. MNs 
were lysed with ice-cold RIPA buffer (150  mM NaCl, 
50 mM Tris–HCl, 2 mM EDTA, 1% Triton X-100, 0.1% 
SDS, 0.5% sodium deoxycholate, pH 7.4; all constituents 
from Sigma-Aldrich®) supplemented with 1X cOmplete 
EDTA-free protease and phosphatase (PhosSTOP) inhibitor 
cocktail tablets (04693159001, 04906837001, Roche Diag-
nostics). MNs were gently scraped off the dish and samples 
were sonicated for 3 × 5 s at amplitude 60% using a Branson 
Digital Sonifier 450 (Branson Ultrasonics), keeping them 
on ice in between pulses. Samples were then centrifuged 
at 16,000 rcf at 4 °C for 10 min and the supernatant was 
retained for protein quantification using a bicinchoninic 
acid assay (23225, Pierce™ Thermo Fisher Scientific). 
20 µg of protein was added to Laemmli buffer [51], whence 
samples were incubated at 37 °C for 30 min prior to being 
loaded onto a Novex™ Tris–glycine gel (XP00145BOX, 
Invitrogen™) and blotted to a polyvinylidene difluoride 
(PVDF)  Immobilon®-FL membrane (05,317, Millipore) 
using 10 mM 3-(Cyclohexylamino)-1-propanesulfonic acid 
(CAPS) buffer pH 11 (C2632, Sigma-Aldrich®) plus 10% 
methanol at 4 °C using a 150 mA transfer for 2 h. Total pro-
tein was quantified using Revert™ 700 Total Protein Stain 
(926–11,015, LI-COR Biosciences) as per manufacturer 
instructions, followed by blocking with  Odyssey® blocking 
buffer in PBS (927–40,000, LI-COR Biosciences) for 1 h at 
room temperature. Thereafter, primary antibody incubation 
in blocking buffer plus 0.2%  Tween® 20 (P9416, Sigma-
Aldrich®) occurred at 4 °C overnight. The membrane was 
then washed with PBST three times and LI-COR  IRDye® 
infrared dyes (1:15,000) added to blocking buffer plus 0.2% 
 Tween® 20 and 0.01% SDS (L3771, Sigma-Aldrich®) for 
1 h at room temperature. The membrane was then washed 
in PBST and imaged using an Odyssey CLx (LI-COR Bio-
sciences). Blots were analysed using Empiria Studio 1.1 (LI-
COR Biosciences). Primary antibodies used in this study 
are: Total OXPHOS Human WB Antibody Cocktail 1:1000 
(ab110411, Abcam), VDAC1/Porin 1:2000 (ab15895, 
Abcam), and GAPDH 1:5000 (CB1001, Sigma-Aldrich®).
Axonal transport studies
MNs, plated on laminin/Matrigel®/fibronectin-coated 
µ-slide 8-well ibidi dishes (80826, ibidi GmbH) at a den-
sity of 50,000–70,000 cells per well were sparsely trans-
duced with lentivirus expressing mitoDsRed2 at platedown 
using an MOI of 0.5, optimised to visualise 1–2 labelled 
cells per field of view, as previously described by our group 
[37, 56]. Fluorescence live-cell imaging of mitochondrial 
axonal transport was performed at day 21 post platedown 
at 63X magnification (Plan-Apochrat 1.40 NA oil DIC M27 
objective, Carl Zeiss) using an Axio Observer Z1 inverted 
motorised microscope (Carl Zeiss) equipped with a Cy3 
FL filter-set (Carl Zeiss), Zen 2011 z-stack, time lapse and 
Definite Focus modules (Carl Zeiss), and an S1 Environ-
mental System (Carl Zeiss) incubation chamber maintained 
at 37 °C and 5%  CO2. Medium was changed 30 min prior 
to imaging to phenol red-free Neurobasal™ (12348017, 
Gibco™ Thermo Fisher Scientific) supplemented with 1X 
GlutaMAX™. Mitochondrial motility was recorded for 
5 min using a 0.2 Hz capture of a ~ 100 µm stretch of axon 
and a small z-stack. ‘Proximal’ axon measurements were 
acquired from the axon immediately adjoining the cell body, 
and ‘distal’ were measured from the distal tip. At least four 
axons (n) were imaged per line per differentiation (N, where 
N = 3). MN genotype was counterbalanced and interleaved 
between experimental runs. Maximum intensity projections 
were computed in Fiji. Kymographs were generated and ana-
lysed using KymoToolBox [113] in Fiji [89] to determine the 
numbers of stationary (≤ 0.1 µm/s) versus bidirectionally 
motile mitochondria (either predominantly towards or away 
from the soma).
Metabolic profiling
MNs were plated on polyethyleinimine (2.2  mg/ml in 
0.1 M borate buffer, pH 8.4; 408727 and B3545, Sigma-
Aldrich®)-treated V28 Seahorse plates (100882-004, 
Agilent), that had been coated overnight with laminin/
Matrigel®/fibronectin as described above, at a high density 
(200,000 cells per well) to ensure the presence of a conflu-
ent cellular monolayer. A modification of the standard Agi-
lent Seahorse XF Cell Mito Stress Test protocol was per-
formed at day 14 post platedown using a Seahorse XFe24 
Analyzer (Agilent), providing a complete mitochondrial 
bioenergetic profile, revealing critical information not evi-
dent in basal metabolism measurements alone. Cells were 
transitioned from the MN-NF medium to low-buffering 
capacity Seahorse XF Base Medium (102,353, Agilent) 
supplemented with 1X Glutamax™, 10  mM glucose 
(Sigma-Aldrich®) and 2 mM pyruvate (Sigma-Aldrich®), 
pH 7.35 ± 0.5 at 37 °C and maintained in ambient  CO2 for 
30 min prior to the plate being inserted into the machine. 
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Oxygen consumption rate (OCR), an indicator of oxidative 
phosphorylation and therefore mitochondrial respiration, 
and extracellular acidification rate (ECAR), an indicator 
of lactate export and anaerobic glycolysis, were measured 
during sequential injection of optimised concentrations 
of oligomycin (3 μM; Sigma-Aldrich®), carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP; Cayman 
Chemical, Cambridge Bioscience), antimycin/rotenone 
(3 μM; Sigma-Aldrich®), and 2-deoxy-d-glucose (1 M; 
D6134, Sigma-Aldrich®). FCCP dose was optimised for 
each cell line (low: 0.125 μM; medium: 0.25 μM; high: 
0.5 μM) and the concentration adopted that maximised 
the OCR response. The protocol adopted a 3 min mixing, 
2 min wait, 3 min measure cycle (i.e., cycle total duration 
of 8 min). Three measurements were taken basally (i.e., 
three cycles with a total duration of 24 min), and three 
measurements were taken after injection of each drug (in 
sequence: oligomycin for inhibiting ATP-linked respira-
tion, FCCP for eliciting maximal uncoupled respiration, 
antimycin/rotenone for inhibiting the electron transport 
chain, and 2-deoxy-d-glucose for terminating glycoly-
sis; see Supplementary Fig. 2a, 2b, online resource). The 
measured OCR was normalised to total protein [23] using 
the bicinchoninic acid assay (23225, Pierce™ Thermo 
Fisher Scientific). A minimum of four individual wells 
(n ≥ 4) per line were included per plate, with experi-
ments repeated in three independent cultures from differ-
ent differentiations (N = 3). Data were visualised in, and 
imported from, Seahorse Wave Desktop software (ver-
sion 2.6.0.31, Agilent). Basal respiration was calculated 
by subtracting the minimum OCR value after antimycin/
rotenone injection (measurement cycle 12) from the OCR 
value prior to injection of oligomycin (measurement cycle 
3). FCCP-stimulated maximal uncoupled respiration was 
calculated by subtracting the minimum OCR after anti-
mycin/rotenone injection (measurement cycle 12) from 
the maximum OCR after FCCP injection (measurement 
cycle 7). Basal glycolytic rate was estimated by subtracting 
the ECAR value immediately after injection of 2-deoxy-
d-glucose (measurement cycle 13) from the ECAR value 
immediately prior to the addition of oligomycin (measure-
ment cycle 3). Respiratory-inhibited maximal glycolysis 
was inferred by subtracting the ECAR value immediately 
after the injection of 2-deoxy-d-glucose (measurement 
cycle 13) from the ECAR value immediately prior to the 
injection of 2-deoxy-d-glucose (measurement cycle 12).
Post‑mortem case identification
We identified a cohort of five C9orf72-ALS cases (from 
the Medical Research Council Edinburgh Brain Bank; 
Table 2) and five age- and sex-matched control cases (from 
the Sudden Death Brain Bank, with no neurological disor-
der during life and no significant neuropathology present 
at post-mortem; Supplementary Table 2, online resource) 
for neuropathological assessment of ventral and dorsal 
spinal cord, as adopted in our previously published work 
[40, 65, 92]. All clinical data were collected as part of 
Scottish Motor Neurone Disease Register (SMNDR) and 
Care Audit Research and Evaluation for Motor Neurone 
Disease (CARE-MND) platform (ethics approval from 
Scotland A Research Ethics Committee 10/MRE00/78 
and 15/SS/0216). Additionally, all cases had correspond-
ing whole-genome sequencing and diagnostic repeat 
prime PCR, demonstrating pathogenic repeat lengths in 
the C9orf72 locus [53]. The use of human tissue for post-
mortem studies has been reviewed and approved by the 
Edinburgh Brain Bank ethics committee and the Academic 
and Clinical Central Office for Research and Development 
medical research ethics committee, in line with the Human 
Tissue (Scotland) Act 2006.
Table 2  Clinical meta-data for C9orf72 cases used in post-mortem work
UL upper limb, LL lower limb, F female, M male









Classification based on El 
Escorial criteria[60]
Past medical history Smoker Alcohol intake Pre-
scribed 
riluzole
Case 1 (F) 63 25 UL and LL Amyotrophic lateral sclero-
sis (definite)
Migraine Ex Yes No




Sarcoidosis Ex No Yes




Lumbar discectomy Yes Yes Yes




Nil known No Yes No
Case 5 (M) 58 87 UL and LL Amyotrophic lateral sclero-
sis (definite)
Lower back pain Yes Yes Yes
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BaseScope™ RNA in situ hybridisation
Formalin-fixed paraffin embedded human post-mortem 
spinal cord tissue was sectioned at 4 µm thickness onto 
SuperFrost Plus™ slides (10149870, Fisher Scientific, 
Thermo Fisher Scientific) as previously reported [40], and 
BaseScope™ reagents (Advanced Cell Diagnostics™ Bio-
Techne) were used as per manufacturer’s guidelines [106]. 
In brief, following deparaffinisation, tissue sections were 
incubated with hydrogen peroxide for 10 min at room tem-
perature and target antigen retrieval was performed by sub-
merging slides in BaseScope™ 1X target retrieval reagent at 
99 °C in a Braun Multiquick FS 20 steamer for 15 min. The 
tissue was then permeabilised using BaseScope™ protease 
III at 40 °C for 30 min. Probe hybridisation was then per-
formed by incubating the slides with four drops of custom-
designed BaseScope™ probe: either BA-Hs-MT-ND2-3zz-st 
(853271, Advanced Cell Diagnostics™ Bio-Techne) or BA-
Hs-MT-CO3-1zz-st (717961, Advanced Cell Diagnostics™ 
Bio-Techne), to recognise ND2 and CO3 mRNA transcripts, 
respectively, or negative control (l-2,3-dihydrodipicoli-
nate reductase, DapB) or positive control (peptidyl-prolyl 
cis–trans isomerase, PPIB) probe for 2 hours at 40 °C. Fol-
lowing successive probe amplification steps, transcripts were 
detected using the BaseScope™ RED detection kit (322910, 
Advanced Cell Diagnostics™ Bio-Techne) and slides were 
counterstained using haematoxylin and lithium carbonate. 
The slides were subsequently cleared in xylene and mounted 
on a 24 × 50 mm coverslip using two drops of  VectaMount® 
mounting medium. Sections were then imaged at 20 × mag-
nification on a NanoZoomer slide scanner (Hamamatsu), 
and the relative neuronal abundance of transcripts (denoted 
by counting the number of spots per cell) was assessed by 
neuropathologists, blinded to the demographic and clini-
cal metadata underlying each sample. Motor and sensory 
neurons were identified based on their anatomical location 
within the spinal cord, and according to established neuro-
pathological criteria, including size and morphology.
BaseScope™ DNA in situ hybridisation
To examine for mitochondrial DNA copy number changes 
in post-mortem spinal cord neurons, we adapted a recently 
published, validated technique [21], permitting the applica-
tion of BaseScope™ to achieve cell-type specific quantifi-
cation. We optimised the BaseScope™ technique on con-
trol and diseased tissue to address probe specificity; thus, 
DNase treatment (optimised specifically to retain haema-
toxylin counterstaining, but eliminate probe binding, con-
firming that the probes were binding to DNA, and not RNA) 
and RNase treatment (optimised specifically to assess the 
extent of background probe binding to RNA, confirming that 
probes were binding to DNA, and not RNA) was carried 
out at 40 °C at a concentration of 800U/ml for DNase and 
RNase for 30 min immediately following the protease III 
tissue permeabilisation step, and prior to probe hybridisa-
tion. Probe hybridisation was then performed by incubating 
the slides with four drops of custom-designed BaseScope™ 
probe (BA-Hs-MT-CO1-3zz-st-sense; 891111, Advanced 
Cell Diagnostics™ Bio-Techne), targeting the antisense 
region of the MT-CO1 gene (i.e., the reverse-complement 
sequence of 273–402 of NC_012920.1:5904–7445) to bind 
to DNA, for 2 h at 40 °C. The method [21] elegantly profits 
on the fact that, although transcription of the circular mito-
chondrial DNA is bidirectional, meaning that theoretically 
probes could hybridise to either DNA or RNA (with result-
ant ambiguity in signal interpretation), most light strand 
transcripts are rapidly degraded, including those antisense 
to the MT-CO1 gene [12, 68]. The Fast RED chromogen 
incubation step was reduced from 10 to 8 min. Sections were 
imaged, anonymised, at 20 × magnification using a Nano-
Zoomer slide scanner (Hamamatsu). Motor and sensory 
neurons were identified based on their anatomical location 
within the spinal cord and according to established neuro-
pathological criteria, including size and morphology. The 
relative abundance of spots (denoting DNA) was quantified 
by neuropathologists, blinded to the demographic and clini-
cal metadata underlying each sample, assessing the mean 
(± standard error) number of spots per cell across ten cells 
per condition. Notably, assuming that each motor neuron is 
circa 50 µm in maximum dimension, and that the photomi-
crograph captures only one 4 µm z-plane (range of spots per 
cell per 4 µm z-plane is between 1 and 8 dots), we anticipate 
that the average spots per cell equates to between 50 and 
400 spots per cell.
Post‑mortem tissue immunohistochemistry
Sections were dried overnight at 40 °C and immunostain-
ing was performed, following epitope retrieval in citric acid 
buffer (pH 6) in a pressure cooker for 30 min, using the rab-
bit anti-MT-ND2 polyclonal antibody (PA5-103952, Invitro-
gen™ Thermo Fisher Scientific) at a 1:200 dilution and rab-
bit anti-MT-CO3 antibody (HPA042788, Sigma-Aldrich®) 
at a 1:50 dilution (both incubated for 30 min at room tem-
perature). Immunohistochemical detection was performed 
using DAB chromogen counterstained with haematoxylin, 
according to standard operating procedures. The immuno-
histochemical staining pattern was noted to be dichotomous 
in nature (i.e., displaying either high intensity or low inten-
sity); consequently, ND2 and CO3 mitochondrial staining 
intensity was graded semi-quantitatively, as low intensity 
(‘intensity 1’) or high intensity (‘intensity 2’), in line with 
other semi-quantitative staining patterns, such as the All-
red oestrogen receptor (ER) histoscore used for prognosti-
cation in the breast cancer field [69, 101]. The percentage 
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of neurons (n = 10 cells per case/control) falling into these 
staining intensity categories was recorded by neuropatholo-
gists, blinded to all demographic and clinical information. 
Statistical analysis was performed using a two-tailed chi-
squared test with Yates’s correction (to reduce approxima-
tion error associated with small sample sizes) on integer 
means of immunoreactivity scores comparing ‘intensity 1′ 
with ‘intensity 2′ staining profiles across cases and controls 
(Supplementary Table 3, online resource).
Data analysis
Statistical analysis was performed using  SPSS® Statistics for 
Windows version 25  (IBM® Corp) or Prism version 8.4.0 
(GraphPad Software). Data are presented as mean ± standard 
error. Data were initially determined to be parametric or non-
parametric before applying the appropriate statistical analy-
sis, with false discovery rate (FDR) correction for multiple 
comparisons, as stated. *p < 0.05, **p < 0.01, ***p < 0.001, 
and ‘ns’ denotes a non-significant result (p ≥ 0.05).
Data availability
The data that support the findings of this study are available 
from the corresponding authors upon reasonable request.
Results
C9orf72 MNs display dysfunctional axonal 
homeostasis associated with mitochondrial 
bioenergetic dysfunction
We generated highly enriched spinal cord MNs from three 
independent C9orf72 iPSC lines and their corresponding 
isogenic controls, as previously reported by our group [92]. 
To investigate the consequence of the C9orf72 repeat expan-
sion mutation on MN axonal homeostasis, we first assessed 
axonal morphology and transport. We observed that C9orf72 
MNs, when compared with their isogenic controls, have sig-
nificantly shorter axons (Fig. 1a, 1b; Supplementary Fig. 1, 
online resource), and fewer motile mitochondria in both the 
proximal (Fig. 1c) and distal (Fig. 1d) axon, as assessed by 
live imaging of MNs transduced with mitoDsRed2 (Supple-
mentary Video 1a, 1b, online resource). To investigate for 
the presence of associated deficits in MN cellular metabo-
lism, we profiled C9orf72 MNs cellular energetics (Supple-
mentary Fig. 2a, 2b, online resource). We found impaired 
basal (Fig. 1e) and maximal (Fig. 1f) mitochondrial respira-
tion, despite normal axonal mitochondrial number (Fig. 1g) 
and mitochondrial copy number (Fig.  1h), implicating 
abnormalities in the electron transport chain machinery 
and/or mitochondrial substrate provision, necessary for 
maintenance of electron flow. Undifferentiated iPSCs did 
not demonstrate the mitochondrial deficit (Supplementary 
Fig. 2c, 2d, online resource), implying neuronal specific-
ity. We also observed no change in the glycolytic function 
in the C9orf72 MNs, suggesting that glycolysis is neither 
involved in a negative nor compensatory fashion (Supple-
mentary Fig. 2e, 2f, online resource).
Transcriptomic analysis of C9orf72 MNs reveals 
reduced expression of mitochondrially encoded 
transcripts of the mitochondrial respiratory chain
To identify putative dysregulated molecular pathways that 
may contribute to these axonal morphological and func-
tional deficits, we next examined the C9orf72 MN tran-
scriptome by performing RNA-seq on two pairs of C9orf72 
and isogenic control MNs, and two independent controls. 
We observed a high degree of similarity between the tran-
scriptome of mutant C9orf72 MNs and their corresponding 
isogenic control (Supplementary Fig. 3a, online resource). 
Differential gene expression analysis identified 215 dys-
regulated transcripts (95 upregulated and 120 downregu-
lated) (Fig. 2a; Supplementary Data 1, online resource). 
Gene ontology analysis revealed, inter alia, dysregulation 
in pathways implicated in axonal homeostasis and oxida-
tive phosphorylation (Fig. 2b; Supplementary Data 1, online 
resource).
It is known that mitochondrial proteins are nuclear-
encoded and mitochondrial DNA-encoded. Intriguingly, we 
found the mitochondrially encoded transcripts to be specifi-
cally downregulated in C9orf72 MNs using competitive gene 
set testing, where two gene sets of interest (for mitochondrial 
DNA-encoded mitochondrial proteins and nuclear-encoded 
mitochondrial proteins) were each compared with all other 
genes; mitochondrially encoded transcripts (p = 7.39 × 10–20) 
but not nuclear-encoded mitochondrial transcripts (p = 0.51) 
were significantly down-regulated (Fig. 2c, d). Furthermore, 
the nine mitochondrially encoded transcripts (contributing to 
complexes I and IV of the electron transport chain, and the 
mitochondrial small and large ribosomal subunits; Fig. 2e) 
whose expression was reduced are all present on the heavy 
strand of the mitochondrial DNA duplex, whereas the light 
strand transcripts, which notably encode for mitochondrial 
tRNAs, were unaltered (Supplementary Fig.  3b, online 
resource).
Quantitative RT-PCR of a representative panel of pre-
dicted dysregulated (MT-ND2 and MT-ND4 subunits of 
electron transport chain complex I, and MT-CO2 and 
MT-CO3 subunits of complex IV) and unaltered (MT-
ATP6 subunit of complex V) mitochondrially encoded 
transcripts, and western blotting analysis of five OXPHOS 
complexes, were next undertaken from all three mutant-





This confirmed dysregulation of various subunits of the 
electron transport chain, most notably complex I and IV 
(Fig. 2f, g; Supplementary Fig. 3c, online resource).
We next performed promoter analysis on the dysregu-
lated genes to identify putative common transcriptional 
factor family regulatory control (Supplementary Data 1, 
online resource). This showed an overrepresentation of 
potential transcription factor binding site motifs for the 
nuclear respiratory factor 1 (NRF1) transcription factor 
family, when compared with all other transcription factor 
families (Promoter Z score = 31.87).
Examination of human C9orf72 post‑mortem spinal 
cord tissue using BaseScope™ shows MN‑selective 
reduced expression of complexes I and IV 
of the mitochondrial electron transport chain
To evaluate the in vivo relevance and selectivity of the 
observed in vitro transcriptional signature, we performed 
neuropathological analysis of human spinal cord motor neu-
rons and sensory neurons. We used BaseScope™ to examine 
the expression of complex I (MT-ND2) and IV (MT-CO3) 
transcripts, in post-mortem samples from C9orf72-ALS 
cases (N = 5) and age- and sex-matched non-neurological 
controls (N = 5). We found significantly reduced expression 
of both MT-ND2 and MT-CO3 in ventral horn spinal motor 
neurons (Fig. 3a; Supplementary Fig. 4, online resource), 
but not in dorsal horn sensory neurons (Fig. 3b; Supple-
mentary Fig. 4, online resource). Thus, these data confirm, 
in human autopsy cases, that the C9orf72 repeat expansion 
mutation results in down-regulation of genes associated 
with the mitochondrial electron transport chain, and that this 
dysregulation is selective to anterior horn (motor) neurons. 
Consistent with this transcriptional signature, we observed 
concomitant changes at the level of protein expression (Sup-
plementary Fig. 5, online resource).
To exclude the possibility of reduced mitochondrial 
DNA driving the transcriptional signature in C9orf72-ALS 
MNs, we next quantified mitochondrial DNA copy number 
through a BaseScope™ DNA in situ hybridisation tech-
nique that uses a probe targeting the antisense strand of the 
MT-CO1 gene (see Materials and Methods). This showed 
unaltered mitochondrial copy number in neurons from cases 
versus controls, both in the ventral and dorsal horn spinal 
cord (Fig. 4).
C9orf72‑dependent dysfunctional axonal 
homeostasis is caused by mitochondrial 
bioenergetic dysfunction
Peroxisome proliferator-activated receptor gamma coacti-
vator 1α (PGC1α) is a master regulator of mitochondrial 
energy metabolism and biogenesis [57], which are usually 
inextricably coupled [111]. PGC1α overexpression, through 
the modulation of the activity of multiple transcription fac-
tors (including NRF1), increases the expression of mito-
chondrial DNA-encoded and nuclear-encoded mitochondrial 
proteins [111], and it improves individual mitochondrial 
function [6], which, in turn, stimulates mitochondrial bio-
genesis [7, 88, 102]. We therefore hypothesised that over-
expressing PGC1α, thereby increasing cellular bioenergetic 
function and mitochondrial biogenesis, may be sufficient to 
rescue the observed axonal phenotypes in C9orf72 MNs.
Accordingly, we performed lentiviral-mediated over-
expression of PGC1α, the expression of which was itself 
Fig. 1  C9orf72-dependent dysfunctional axonal homeostasis is asso-
ciated with impaired mitochondrial bioenergetic function in  human 
iPSC-derived MNs. a Quantification of SMI-312 antibody-labelled 
axonal length in MNs 7 days post platedown (n = 50 axons per inde-
pendent MN differentiation, N = 3 independent differentiations; data 
are represented as mean ± SEM; genotypes used: two independent 
controls [Con-1, Con-2], three independent patient-derived C9orf72 
lines [C9-1, C9-2, C9-3] with their corresponding isogenic controls 
[C9-1Δ, C9-2Δ, C9-3Δ]; statistical significance was evaluated using 
a mixed-effects negative binomial regression with fixed effects for 
mutant/isogene status and random effects for genotype, with paired 
mutant-isogene statistics performed via the Mann–Whitney test with 
FDR correction for multiple comparison testing). b Representative 
images depicting axonal staining via SMI-312 immunocytochemis-
try of day 7 post platedown C9orf72 (C9) and paired isogenic con-
trol (C9Δ) MNs (scale bars = 100  µm). Quantification of the per-
centage of motile mitochondria (labelled with mitoDsRed2) relative 
to the total number of mitochondria in a 100 µm stretch of proximal 
(c) and distal (d) axon in C9orf72-MNs and isogenic paired controls; 
two independent healthy controls are shown. Data are represented as 
mean ± SEM; n ≥ 4 axons per independent MN differentiation, N = 3 
independent differentiations. Statistical significance was evaluated 
with the Kruskal–Wallis test with FDR correction. Quantification of 
the oxygen consumption rate (OCR) as measured by the Seahorse 
Analyzer, normalised to the amount of total protein, denoting basal 
(e) and maximal FCCP-uncoupled (f) mitochondrial respiration for 
C9orf72-MNs and isogenic paired controls; two independent healthy 
controls are also shown. Data are represented as mean ± SEM; n ≥ 4 
wells per line per experiment, with experiments repeated in three 
independent cultures from different differentiations (N = 3). Statisti-
cal significance was evaluated with one-way ANOVA with post hoc 
mutant-isogene paired FDR-corrected t tests. g, Quantification of the 
axonal mitochondrial number in a 100  µm stretch of distal axon in 
C9orf72-MNs and isogenic paired controls; two independent healthy 
controls are also shown. Data are represented as mean ± SEM; n = 10 
axons per line per experiment, with experiments repeated in three 
independent cultures from different differentiations (N = 3). Statistical 
significance was evaluated with one-way ANOVA. h Quantification 
of mitochondrial DNA copy number in C9orf72-MNs and isogenic 
paired controls; two independent healthy controls are also shown. 
Data are represented as mean ± SEM, with experiments repeated 
in at least three independent cultures from different differentiations 
(N ≥ 3). Statistical significance was evaluated with the Kruskal–Wal-
lis test with FDR correction. *p < 0.05, **p < 0.01, ***p < 0.001, ‘ns’ 




unchanged basally between mutants and isogenic C9orf72 
MNs (Supplementary Fig. 6, online resource). This resulted 
in the restoration of the expression of mitochondrial tran-
scripts (complex I: MT-ND4 and complex IV: MT-CO3) 
of the electron transport chain (Fig. 5a–c), together with 
an increase in mitochondrial number in the distal axon 
(Fig. 5d). This in turn led to rescue of the C9orf72-dependent 
impairment in basal (Fig. 5e) and maximal (Fig. 5f) mito-
chondrial function. Critically, boosting mitochondrial bio-
energetics was sufficient to rescue both the axonal length 
(Fig. 5g) and mitochondrial transport (Fig. 5h; Supplemen-
tary Video 2a, 2b, online resource) phenotypes observed 
in C9orf72 MNs. Taken together, these data establish a 
novel mechanistic link between mitochondrial bioenergetic 
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dysfunction and axonal dysfunction in the pathophysiology 
of C9orf72-ALS.
Discussion
Our human in vitro and neuropathological post-mortem find-
ings establish, for the first time, the presence of metabolic 
deficits in C9orf72-ALS MNs, owing to loss of mitochon-
drial bioenergetic function. Through the use of isogenic con-
trols, and pathway manipulation derived from unbiased tran-
scriptomics, we further show a novel causal and mechanistic 
link between MN bioenergetic failure and axonal dysfunc-
tion. Given the particular vulnerability of MNs to metabolic 
stress [52], our findings suggest a cell-autonomous mecha-
nism to explain the selective MN degeneration found in ALS 
[74], and further confirm that ameliorating mitochondrial 
function is an area of therapeutic promise [66].
It is well established from animal models of ALS that 
targeting the axon leads to delayed onset of disease and 
improved survival [90, 93, 95] and that preventing MN loss 
alone, but not axonal degeneration, is inadequate for promot-
ing survival [82]. Given that importance of maintenance of 
axonal homeostasis, it is thus important to better understand 
the impact of the C9orf72 repeat expansion mutation on 
human MN axonal properties. In the present study, we found 
two axonal phenotypes underlying dysfunctional axonal 
homeostasis in C9orf72 MNs. First, we demonstrate a novel 
phenotype of impaired fast axonal transport of mitochondrial 
cargo in C9orf72 MNs. Second, we discovered a novel mor-
phological deficit—of shorter MN axonal length—consist-
ent with phenotypic observations across other, rarer, ALS 
mutations, such as SOD-1 [20, 48] and TDP-43 [17, 33, 34, 
49], as well as sporadic ALS [36]. While to our knowledge 
this is the first report of these phenotypes in C9orf72 human 
iPSC-derived MNs, reduced mitochondrial trafficking has 
recently been shown in primary cortical excitatory neurons 
in an inducible mouse model of poly(GR) toxicity [22]. The 
precise underlying pathological mechanisms of C9orf72-
ALS remain unclear, with non-mutually exclusive C9orf72 
haploinsufficiency and toxic gain of function mechanisms 
implicated. Recent work from Sivadasan et al. showed mod-
ulation of C9orf72 protein levels in mouse primary MNs 
influences actin cytoskeletal dynamics and axon outgrowth 
[96]. However, in neurons, the primary mediator of long-
range mitochondrial transport is via microtubule-based 
motor machinery. In addition, it has been recently showed 
that C9orf72 loss of function alone does not contribute to 
lysosomal fast axonal transport deficits in C9orf72 iPSC-
derived MNs [1]. Previous C9orf72 human iPSC studies by 
ourselves [92, 115], and others [1], showing pathological 
dipeptide repeat proteins and RNA foci, but not reduction 
in expression of C9orf72 (both at transcriptomic and pro-
tein levels), suggest that the observed dysfunctional axonal 
homeostasis is due to toxic gain of function mechanisms 
[16].
A key component of either the dying backward [35, 71] or 
the dying forward model [15] of neurodegeneration is axonal 
transport [8]. Thus, perturbations in axonal transport are key 
mediators of neurodegeneration, warranting an improved 
understanding of upstream mechanisms. Mitochondria are 
transported via fast axonal transport to the distal neurites 
and provide the necessary energy for local axonal processes 
that shape neuronal wiring and axon maintenance. Microtu-
bules are critical, as are two main motor proteins—kinesin 
(for anterograde transport) and dynein (for retrograde trans-
port)—in conjunction with axonal actin filaments [45]. The 
processes involved are all highly energy consuming, raising 
the question of whether impairments in energy metabolism 
contribute to defective axonal transport. While impairments 
in microtubule machinery have been observed in a rare ALS-
causing mutation, FUS, leading to axonal transport deficits 
[41], metabolic impairments were unexpectedly shown to be 
Fig. 2  Transcriptomic analysis revealed reduced gene expression of 
the mitochondrial electron transport chain in  human iPSC-derived 
C9orf72-MNs. a Results of differential gene expression analysis, 
using DESeq2, examining the intersection in commonly and concord-
antly differentially expressed genes between the two mutant-isogene 
pairs, using an FDR of 20%, and discarding genes with an average 
FPKM < 1. The scatter plot shows the comparison of gene expres-
sion (as average FPKM). Red and blue data points denote the over-
lap of significantly up- and down-regulated genes in both mutant-
correction pairs, respectively. b Summary of notable results from 
gene ontology analysis performed on the differentially expressed 
genes that identified putatively up (red) and down (blue) regulated 
altered pathways or processes. Average FPKM scatter plots compar-
ing gene expression in C9orf72 mutant versus isogenic controls for 
two gene sets of interest (c, mitochondrially encoded mitochondrial 
transcripts and (d) nuclear-encoded mitochondrial transcripts). Com-
petitive gene set testing using CAMERA, examining the differential 
gene expression for these two gene sets of interest compared with all 
other genes, showed that mitochondrially encoded transcripts were 
down-regulated (p = 7.39 × 10–20), whereas nuclear-encoded mito-
chondrial transcripts were not (p = 0.51). e Heatmap summarising the 
average gene expression (FPKM) of significantly dysregulated genes 
of complex I (MT-ND1, MT-ND2, MT-ND4, MT-ND4L, MT-ND5) 
and complex IV (MT-CO2, MT-CO3) subunits of the electron trans-
port chain for C9orf72 versus isogenic control MNs. f  Log10 mean 
fold change ± SEM of gene expression normalised to the respective 
isogenic control determined via RT-PCR for C9-1 pair (black bars), 
C9-2 pair (red bars), and C9-3 pair (green bars) for MT-ND2 and 
MT-ND4 subunits of complex I; MT-CO2 and MT-CO3 subunits of 
complex IV; and MT-ATP6 subunit of complex V. g Representative 
image of western blot of protein lysates from two independent con-
trols [Con-1, Con-2], three independent patient-derived C9orf72 lines 
[C9-1, C9-2, C9-3] with corresponding isogenic controls [C9-1Δ, 
C9-2Δ, C9-3Δ] using a primary  Total OXPHOS cocktail antibody 
against multiple mitochondrial electron transport chain subunits. 
Bands depict protein expression of complex I (NDUFB8; reduced), 
complex II (SDHB), complex III (UQCRC2), complex IV (MT-CO2; 
reduced) and complex V (ATP5A), and housekeeper proteins against 




absent [104]. Indeed, until the present study, it has not been 
shown that ALS patient-derived MNs metabolically differ 
from healthy MNs. In contrast, we report a cell-autonomous 
bioenergetic functional deficit in ALS human iPSC-derived 
MNs. Mitochondrial metabolic function was impaired, with 
neither a concomitant difference in glycolysis, nor altered 
metabolic state in the parental iPSC lines. Unbiased bulk 
RNA-sequencing and transcriptomic analysis revealed a 
distinct mitochondrial signature, with reduction in expres-
sion of mitochondrial-DNA encoded transcripts relating to 
the electron transport chain. Importantly, this mitochondrial 
loss of function signature was recapitulated in patient spinal 
cord tissue in a selective manner; thus, ventral horn motor 
neurons—but not dorsal horn sensory neurons—displayed 
down-regulation of expression of transcripts relating to com-
plexes I and IV of the electron transport chain. In addition to 
Fig. 3  Examination of human C9orf72 post-mortem spinal cord tis-
sue shows reduced expression of complexes I and IV of the mitochon-
drial electron transport chain in ventral horn motor, but not dorsal 
horn sensory, neurons. a Representative photomicrographs showing 
reduced expression of MT-ND2 (complex I) and MT-CO3 (complex 
IV) transcripts in ventral horn motor neurons of the post-mortem spi-
nal cord from a C9orf72 hexanucleotide repeat expansion mutation 
case compared with its age- and sex-matched control. Red spots high-
light individual mRNA molecules of MT-ND2 or MT-CO3. Tissue 
was counterstained with haematoxylin. Scale bars = 50  µm. Orange 
asterisk denotes an anterior horn motor neuron. Bar chart depicts 
the quantification of the number of MT-ND2 and MT-CO3 tran-
scripts per ventral horn spinal motor neuron. Bars represent aggregate 
mean ± SEM, with each dot representing the mean count for between 
one and five cells for each of the five post-mortem specimens for 
C9orf72-ALS (red bars) and their age- and sex-matched controls 
(blue bars). Statistical significance was evaluated with the Kruskal–
Wallis test with FDR correction. b Representative photomicrographs 
of the dorsal horn sensory neurons, examined using the same probes 
that recognise individual mRNA of MT-ND2 or MT-CO3, showing 
comparable expression between the same cases and controls. Scale 
bars = 50 µm. Orange asterisk denotes a dorsal horn sensory neuron. 
Bar chart depicts the quantification of the number of MT-ND2 and 
MT-CO3 transcripts per dorsal horn neuron. Bars represent aggregate 
mean ± SEM, with each dot representing the mean count for between 
one and five cells for each of the five post-mortem specimens for 
C9orf72-ALS (red bars) and their age- and sex-matched controls 
(blue bars). Statistical significance was evaluated with the Kruskal–
Wallis test with FDR correction for multiple comparisons. *p < 0.05, 
**p < 0.01, ‘ns’ denotes non-significant result (p ≥ 0.05)
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the observation of no difference in expression in the dorsal 
horn neurons (acting as an internal control), previous find-
ings of an upregulation of the GRIA1 transcript in ventral 
spinal MNs from the same C9orf72-ALS cases [40, 92] 
suggest that the observed down-regulation of mitochondrial 
gene expression in ventral horn spinal motor neurons is not 
due to a non-specific post-mortem artifact. Furthermore, 
mitochondrial copy number is known to be unchanged in 
ALS cases in general compared to controls [108]. Indeed, 
our in vitro and post-mortem findings together also exclude 
the possibility of a reduction in mitochondrial copy number 
in C9orf72-ALS. Consistent with these findings, we did 
not observe significant changes in either axonal mitochon-
drial counts or transcript levels of mitochondrial tRNAs in 
C9orf72 MNs. The trend towards increased mitochondrial 
copy number observed in C9orf72-MNs may reflect a com-
pensatory response to the mitochondrial transcriptional dys-
regulation. Taken together, we conclude that the observed 
reduced mitochondrial gene expression signature and con-
comitant metabolic deficit are not mechanistically driven by 
reduced mitochondrial DNA.
Fig. 4  Mitochondrial DNA copy number in human C9orf72 post-
mortem spinal cord tissue is unaltered. a Representative photomi-
crographs showing DNA in situ hybridisation in control ventral horn 
spinal cord tissue. Red spots denote probe binding to MT-CO1—a 
surrogate of mitochondrial DNA copy number. RNase treatment 
resulted in no change in signal, while DNase treatment resulted in 
elimination of signal, confirming that the probe binds to DNA, and 
not RNA. Tissue was counterstained with haematoxylin and images 
were acquired at 40 × magnification. Scale bars = 20  µm. b Repre-
sentative photomicrographs showing unaltered mitochondrial copy 
number in a C9orf72 hexanucleotide repeat expansion mutation 
case compared with its age- and sex-matched control, both in spinal 
cord ventral horn motor neurons (upper panel) and dorsal horn sen-
sory neurons (lower panel). Red spots denote probe binding to MT-
CO1. Tissue was counterstained with haematoxylin and images were 
acquired at 40 × magnification. Scale bars = 20 µm. Bar charts depict 
the quantification of the number of spots per neuron in either the ven-
tral (upper panel) or dorsal horn (lower panel). Bars represent aggre-
gate mean ± SEM, with each dot representing the mean count for ten 
cells for each of the five post-mortem specimens for C9orf72-ALS 
(red bars) and their age- and sex-matched controls (blue bars). Sta-
tistical significance was evaluated with the Mann–Whitney test; ‘ns’ 





The molecular basis of how the C9orf72 repeat expan-
sion mutation results in transcriptional dysregulation of 
mitochondrial electron transport chain genes is unclear. 
Future studies will also need to evaluate mitochondrial tran-
scriptional status in non-C9orf72 cases, including sporadic 
ALS, as well as in other forms of motor neuron disease, 
such as spinal muscular atrophy [14], to begin to address 
whether our findings are directly related to C9orf72 patho-
genic mechanisms, such as dipeptide repeat proteins and/
or due to, for example, TDP-43 aggregation. Indeed, recent 
findings show that C9orf72 dipeptide repeat proteins can 
lead to cytoplasmic TDP-43 aggregation [24, 99]. Thus, does 
TDP-43 pathology, observed in the vast majority of ALS 
cases, including C9orf72 [4, 72], modulate mitochondrial 
homeostasis by regulating the processing of mitochondrial 
transcripts [46]? Indirect evidence for this idea is supported 
by recent findings of transcriptional dysregulation in path-
ways involved in mitochondrial function and energy pro-
duction in TDP-43-depleted motor neurons [17]. Moreover, 
TDP-43 has been shown to exert toxicity by entering mito-
chondria and specifically impairing OXPHOS complex I 
via the preferential binding of mitochondrially transcribed 
ND3/6 mRNAs and by inhibiting their translation to cause 
mitochondrial dysfunction and neuronal loss [107], as well 
as triggering mitochondrial DNA release and neuroinflam-
matory cGAS/STING activation [112]. Finally, recent work 
by Onesto et al. showed that there is compensatory mito-
chondrial biogenesis, as evidenced by PGC1α upregulation, 
in dermal fibroblasts derived from patients with C9orf72-
ALS [77]. This suggests that, despite carrying the patho-
logical mutation, most cell types can compensate for the 
mitochondrial dysfunction by stimulating biogenesis, and 
selective vulnerability could arise partly from an inability 
of motor neurons to modulate this homeostatic mechanism.
Crucially, notwithstanding an unaltered NRF1-PGC1α 
axis basally in C9orf72 MNs, we were able to boost mito-
chondrial function (and biogenesis) through manipulation of 
its master regulator, PGC1α, leading to rescue of the axonal 
phenotypes, providing a novel mechanistic link between 
mitochondrial bioenergetics and axonal dysfunction. Fast 
axonal transport is a highly energy demanding process [97]. 
Chronic dysfunction of the mitochondrial electron transport 
chain could result in a reduction of global ATP levels in 
MNs. Consequently, motor proteins would arrest, given the 
cellular milieu being deprived of adequate ATP. The suc-
cessful manipulation of a key pathway involved in mito-
chondrial energy metabolism adds to the emerging spinal 
cord injury literature that has shown that restoring cellular 
energetics and axonal transport promotes axonal outgrowth 
and regeneration [42]. Our data suggest that targeting this 
tractable pathway may thus also be highly relevant to neu-
rodegeneration [56, 75], accepting the possibility of there 
being other competing mechanisms driving the dysfunc-
tional axonal homeostasis observed in C9orf72 MNs.
Our findings add important new metabolic functional data 
to the existing ALS mitochondrial literature. Early, elegant 
post-mortem studies (well before the current rich genetic 
landscape of ALS had been determined) showed that patients 
with ALS have dense clusters of mitochondria in the anterior 
horn of the lumbar spinal cord [87] and presynaptic mito-
chondrial swelling in their motor neurons [94]. The cellular 
distribution of mitochondria was also shown to be affected, 
with the majority of mitochondria being located in the soma 
and proximal axon [86]. Moreover, the total amount of mito-
chondrial DNA, measured by Southern blot, was reduced in 
the spinal cord from sporadic ALS patients [109], associ-
ated with a decrease in the activity of the electron transport 
chain complexes in spinal cord mitochondria [109] and a 
Fig. 5  C9orf72-dependent dysfunctional axonal homeostasis is 
caused by mitochondrial bioenergetic dysfunction in  human iPSC-
derived MNs. a–c Mean fold change ± SEM of gene expression nor-
malised to the respective isogenic control (or control) determined via 
RT-PCR; genotypes used: two independent controls [Con-1, Con-2], 
three independent patient-derived C9orf72 lines [C9-1, C9-2, C9-3; 
red bars] with their corresponding isogenic controls [C9-1Δ, C9-2Δ, 
C9-3Δ; blue bars], with (hatched bars) and without (unhatched bars) 
PGC1α overexpression, for transcripts: MT-ND4 (complex I; a), 
MT-CO3 (complex IV; b), and MT-ATP6 (complex V; c). d Quan-
tification of the axonal mitochondrial number in a 100 µm stretch of 
distal axon in C9orf72-MNs and their respective isogenic controls, 
with (hatched bars) and without (unhatched bars) PGC1α overex-
pression. Data are represented as mean ± SEM; n ≥ 4 axons per line 
per experiment, with experiments repeated in three independent cul-
tures from different differentiations (N = 3). Statistical significance 
was evaluated with one-way ANOVA with post hoc mutant-isogene 
paired FDR-corrected t tests. Quantification of the relative oxygen 
consumption rate (OCR) as measured by the Seahorse Analyzer, 
normalised to the amount of total protein, denoting basal (e) and 
maximal FCCP-uncoupled (f) mitochondrial respiration for C9orf72-
MNs and isogenic paired controls, with (hatched bars) and without 
(unhatched bars) PGC1α overexpression. Data are represented as 
mean fold change (relative to C9orf72-ALS) ± SEM; n ≥ 4 wells per 
line per experiment, with experiments repeated in three independent 
cultures from different differentiations (N = 3). Statistical significance 
was evaluated with one-way ANOVA with post hoc mutant-isogene 
paired FDR-corrected t tests. g Quantification of the SMI-312 anti-
body-labelled axonal length in MNs 7  days post platedown, with 
(hatched bars) and without (unhatched bars) PGC1α overexpression 
(n > 15 axons per independent MN differentiation, N = 3 independent 
differentiations; data are represented as mean ± SEM; genotypes used: 
three independent patient-derived C9orf72 lines [C9-1, C9-2, C9-3] 
with their corresponding isogenic controls [C9-1Δ, C9-2Δ, C9-3Δ]; 
statistical significance was evaluated using the Kruskal–Wallis test 
with FDR correction). h Quantification of the percentage of motile 
mitochondria (labelled with mitoDsRed2) relative to the total num-
ber of mitochondria in a 100  µm stretch of axon in C9orf72-MNs, 
with (hatched bars) and without (unhatched bars) PGC1α overexpres-
sion, and isogenic paired controls; two independent healthy controls 
are also shown. Data are represented as mean ± S.E.M; n ≥ 4 axons 
per independent MN differentiation, N = 3 independent differentia-
tions. Statistical significance was evaluated with the Kruskal–Wallis 
test with FDR correction. *p < 0.05, **p < 0.01, ***p < 0.001, ‘ns’ 




reduction in the activity of key mitochondrial enzymes [13]. 
Our study provides a mechanistic link between the func-
tional MN metabolic deficits to alterations in gene expres-
sion. More recently, astrocytic metabolic inflexibility [3] 
and mitochondrial aberrations in patient-derived fibroblasts 
[77] and iPSC models [27, 36, 59] have been demonstrated 
in C9orf72-ALS. C9orf72 patient-derived motor neurons 
have swollen mitochondria on electron microscopy [27], 
a reduced [27] or increased [59] mitochondrial membrane 
potential, associated with altered calcium buffering, contrib-
uting to glutamate excitotoxity [26], and elevated levels of 
cytochrome c [27]. They also show increased age-dependent 
oxidative stress associated with poly(GR) dipeptide repeat 
proteins binding to mitochondrial ribosomal proteins [59], 
and more recently in Drosophila muscle, poly(GR) has been 
shown to interact with components of the ‘mitochondrial 
contact site and cristae organising system’ impacting on 
mitochondrial ion homeostasis [54]. In our study, we show 
a distinct mitochondrial bioenergetic deficit in C9orf72 
MNs. In addition to calcium buffering, mitochondrial bio-
energetics could also contribute to neuronal vulnerability 
to excitotoxicity. PGC1α, which controls cellular energetics 
including mitochondrial biogenesis, has been shown to nega-
tively regulate glutamate receptor mediated excitotoxicity in 
Huntington’s disease mouse models [79]. Indeed, we have 
previously shown that C9orf72 MNs display vulnerability to 
excitotoxicity, owing to dysregulation in glutamate receptors 
[92], and the present findings raise the possibility of there 
being positive feedback on the excitotoxic signalling path-
ways. Finally, a large screening study (> 1200 drugs) from 
32 sporadic ALS human iPSC lines showed that ropinirole, 
a dopamine (D2) receptor agonist used to treat Parkinson’s 
disease motor symptoms, reverses their identified neurite 
length, cytotoxicity and abnormal protein aggregations phe-
notypes, by reducing the elevated reactive oxygen species, 
implicating ropinirole’s non-canonical effects on mitochon-
drial pathways [36].
In summary, our study establishes a novel mechanistic 
link between mitochondrial dysfunction and axonal dysfunc-
tion in ALS using human-based disease modelling. It is con-
ceivable that boosting mitochondrial metabolism locally at 
the growth cone or synapses could improve the size of the 
motor unit by promoting terminal axonal sprouting and/or 
increasing stability of the neuromuscular junction. Accord-
ingly, we believe that our findings highlight the importance 
of targeting mitochondrial dysfunction directly, to discover 
novel therapeutic agents for this devastating disease [66].
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